{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.08","upperLimit":"0.25","value":"0.25"},{"groupId":"OG001","lowerLimit":"0.08","upperLimit":"0.25","value":"0.17"},{"groupId":"OG002","lowerLimit":"0.08","upperLimit":"0.08","value":"0.08"},{"groupId":"OG003","lowerLimit":"0.25","upperLimit":"0.25","value":"0.25"},{"groupId":"OG004","lowerLimit":"1.08","upperLimit":"1.17","value":"1.08"},{"groupId":"OG005","lowerLimit":"1.08","upperLimit":"2.11","value":"1.08"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants in Arm A received 60 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG000","title":"Dose Escalation Cohort 1: RO7297089"},{"description":"Participants in Arm A received 180 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG001","title":"Dose Escalation Cohort 2: RO7297089"},{"description":"Participants in Arm A received 360 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG002","title":"Dose Escalation Cohort 3: RO7297089"},{"description":"Participants in Arm A received 1080 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG003","title":"Dose Escalation Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1080 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose wasadministered at subsequent study drug administration visits.","id":"OG004","title":"Dose Escalation Backfill Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1850 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose was administered at subsequent study drug administration visits.","id":"OG005","title":"Dose Escalation Cohort 5: RO7297089"}],"paramType":"MEDIAN","populationDescription":"Cohorts reported with participants excluded from descriptive statistics due to not receiving the full dose:\n\nCohort 2: 1 participant Cohort 3: 1 participant Cohort 4A: 2 participants Cohort 4B reported with 1 participant excluded from descriptive statistics due to apparent outlier and 1 participant due to or missing sample.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Time to Maximum Concentration Observed (Tmax) of RO7297089","type":"SECONDARY","unitOfMeasure":"EOI, day"}